Losing weight is challenging, and with rising obesity rates in the UK, choosing the right treatment is more important than ever. In 2023-24, 64.5% of adults in England were estimated to be either overweight or living with obesity — and 26.5% were living with obesity alone. Wegovy weight loss injections
One in five adults in the UK now lives with either diabetes or pre-diabetes — that is over 12 million people. Managing type 2 diabetes often means tackling two challenges simultaneously: keeping blood sugar within safe limits and dealing with excess weight. Mounjaro injections are one of the newer treatments
Wegovy injections have quickly become one of the most talked-about treatments for weight loss in the UK. In the SELECT trial (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity), involving over 17,600 adults with overweight or obesity and established cardiovascular disease but no diabetes, Wegovy reduced the
Wegovy for weight loss is arriving at a time when obesity remains a major public health concern in England. According to the latest data, 26.5% of adults in 2023-24 were living with obesity, and about 64.5% were either overweight or obese. Clinical trials such as the STEP programme show that
Obesity is a constantly growing health concern in the UK—recent data shows that 29 per cent of adults in England are living with obesity, and 64 per cent are either overweight or obese. Many are exploring treatments such as Wegovy and Mounjaro. If you are using Wegovy and wondering whether
Losing weight can be challenging, and many people are now exploring prescription weight-loss injections. In fact, NHS data shows that around one in four adults in the UK are living with obesity, making effective weight management an important public health priority. Two of the most talked about treatments for weight
In 2025, weight-loss injections such as Mounjaro and Wegovy continue to attract major attention in the UK. Clinical trials show that Mounjaro users lose an average of around 20% of their body weight, while Wegovy users lose about 14% over a little more than a year. While both medicines can
Obesity is a growing concern, with around 1 in 4 adults in the UK now classed as obese. For many, lifestyle changes alone may not deliver the results they need, which is where prescription treatments like Wegovy come in. Wegovy is a once-weekly injection shown in studies to help people
Mounjaro (tirzepatide) has quickly gained attention for its effectiveness, with clinical trials showing patients losing on average up to 21% of their body weight. With results like these, it’s no surprise that many people considering treatment ask how long Mounjaro stays in the system. Understanding its half-life, effects, and clearance
Losing weight can be a challenging journey, especially when diets and exercise alone do not bring the desired results. In recent years, new treatment options have been developed to support people who struggle with long-term weight issues. One of the most talked-about options today is Wegovy injections. But what exactly
@2026 Touchwood Pharmacy. All Right Reserved.
